Study Evaluating PSI-697 in Patients With Scleritis

Wyeth

Status and phase: Terminated; Phase 1

Conditions: Scleritis

Treatments: Drug: PSI-697

Study type: Interventional

Funder types: Industry

Identifiers

NCT00367692

3165A1-106

Details and patient eligibility

About

To evaluate the safety of an orally administered single dose of PSI-697 in subjects with scleritis, as a model of inflammatory disease. To evaluate by in vivo confocal microscopy (IVCM) the effect of a single dose of PSI-697 on leukocyte rolling in the scleral blood vessels of subjects with scleritis.

Enrollment: 12 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion: Age 18 or higher; A negative urine pregnancy test at screening for female subjects; Female subjects must be postmenopausal or surgically sterile.

Exclusion: Isolated episcleritis; Isolated posterior scleritis; Infectious scleritis.